Nuformix PLC (LON:NFX) chief executive Anne Brindley joins Proactive London with an update on the development its pipeline of repurposed drug assets and negotiations with potential licensing partners.
Brindley explains their ambition alongside the group’s results for year to 31 March. She says they are planning to repurpose existing, marketed drugs, with improved physical properties in order to develop novel products in new indications to create attractive commercial opportunities.
Still with an early-stage pipeline of drugs, the company reported a £1.25mln loss on ordinary activities for the year, compared to £756,376 a year earlier.